US2020347122A1PendingUtilityA1
Cell culture media and methods of antibody production
Est. expiryMar 15, 2033(~6.6 yrs left)· nominal 20-yr term from priority
C07K 16/22A61P 35/00C12N 2501/33C12N 2500/20C12N 2500/32C07K 16/00C07K 2317/14C07K 2317/76C07K 2317/24C12N 5/0682C12N 2501/998C12N 2510/02
63
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Cell culture media are provided herein as are methods of using the media for cell culture and antibody production from cells. Compositions comprising antibodies and fragments thereof, produced by the methods herein are also provided.
Claims
exact text as granted — not AI-modified1 - 225 . (canceled)
226 . A method of producing bevacizumab or a fragment thereof, comprising a step of culturing a mammalian cell comprising a nucleic acid encoding bevacizumab or a fragment thereof in a cell culture medium, wherein initial cell culture medium in a cell culture cycle comprises two or more components selected from the group consisting of copper at a concentration of from about 69 nM to about 1,000 nM, insulin at a concentration of from about 1.0 mg/L to about 100.0 mg/L, and cystine at a concentration of from about 0.7 mM to about 2.0 mM, and wherein the cell produces bevacizumab or the fragment.
227 . The method of claim 226 , wherein the initial cell culture medium comprises (1) copper and insulin; (2) copper and cystine; (3) insulin and cystine; or (4) copper, insulin, and cystine.
228 . The method of claim 226 , wherein the initial cell culture medium comprises insulin at a concentration of from about 10.0 mg/L to about 50.0 mg/L.
229 . (canceled)
230 . (canceled)
231 . The method of claim 226 , wherein the initial cell culture medium comprises copper at a concentration of from about 325 nM to about 375 nM.
232 . (canceled)
233 . (canceled)
234 . The method of claim 226 , wherein the initial cell culture medium comprises cystine at a concentration of from about 0.7 mM to about 2.0 mM.
235 - 246 . (canceled)
247 . The method of claim 226 , wherein the initial cell culture medium comprises insulin and the method further comprises a step of adding an additional amount of insulin to the cell culture medium during the cell culture cycle.
248 . (canceled)
249 . The method of claim 247 , wherein the insulin added each time is from about 5 mg/L to about 25 mg/L.
250 . (canceled)
251 . The method of claim 247 , wherein the cumulative amount of insulin added during the cell culture cycle is from about 20 mg/L to about 100 mg/L.
252 . (canceled)
253 . The method of claim 226 , wherein the initial cell culture medium comprises cystine and the method further comprises a step of adding an additional amount of cystine to the cell culture medium during the cell culture cycle.
254 . The method of claim 253 , wherein cystine is added in an amount to provide from about 0.1 to about 1.5 mM additional cystine in the cell culture medium.
255 . (canceled)
256 . (canceled)
257 . The method of claim 226 , wherein the method further comprises at least one batch feed during the cell culture cycle.
258 . (canceled)
259 . (canceled)
260 . The method of claim 226 , wherein during the cell culture cycle, the temperature of the medium is reduced by at least about 2, at least about 3, at least about 4, or at least about 5 degrees C. relative to the temperature at the beginning of the culturing.
261 - 263 . (canceled)
264 . The method of claim 226 , wherein the cell is cultured at a first temperature of about 35° C. for a first period of time, is cultured at a second temperature of about 33° C. for a second period of time, and is cultured at a third temperature of about 31° C. for a third period of time.
265 . The method of claim 226 , wherein the cell is cultured in the medium having a pH at about 7.0 to about 7.3.
266 . The method of claim 226 , wherein the method comprises (a) culturing the cell in an initial cell culture medium comprising about 10 mg/L insulin, about 325 nM to about 350 nM copper, and about 1.3 mM cystine; (b) providing a first batch feed and an insulin feed to the cell culture medium to provide additional insulin at a concentration of about 15 mg/L on day 3 after the beginning of the culturing; and (c) providing a second batch feed comprising cystine to the cell culture medium to provide additional cystine at a concentration of about 0.4 to about 0.7 mM on day 6 after the beginning of the culturing; wherein the cell is cultured at an initial temperature of about 35° C., and the temperature is reduced to about 33° C. on day 8 and is further reduced to about 31° C. on day 10 after the beginning of the culturing.
267 . The method of claim 226 , wherein bevacizumab or a fragment thereof is secreted into the cell culture medium.
268 . The method of claim 226 , further comprising a step of recovering the bevacizumab or a fragment thereof from the cell culture.
269 . The method of claim 226 , wherein the mammalian cell is a Chinese hamster ovary cell.
270 . Bevacizumab or a fragment thereof produced by the method of claim 226 .
271 . A composition comprising: (i) bevacizumab or a fragment thereof produced by the method of claim 226 and (ii) a pharmaceutically acceptable carrier.Join the waitlist — get patent alerts
Track US2020347122A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.